Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Patrick John Finn net worth and biography

Patrick Finn Biography and Net Worth

Insider of Verona Pharma

Patrick John Finn Ph.D. serves as Chief Commercial Officer of the Company. He is our Senior Vice President of Commercial Operations from December 2018 to October 2019. Prior to joining us, Dr. Finn was Vice President of Sales at Enzymatics Inc., a developer, manufacturer, and marketer of enzymes for molecular biology applications, sold predominantly to manufacturers in research and diagnostic markets from January 2012 to March 2015. Dr. Finn holds a B.Sc. in Chemistry from Heriot-Watt University and a Ph.D. in Chemistry from the University of Southampton.

What is Patrick John Finn's net worth?: The estimated net worth of Patrick John Finn is at least $2.70 million as of April 23rd, 2024. Mr. Finn owns 176,206 shares of Verona Pharma stock worth more than $2,697,714 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Finn may own. Learn More about Patrick John Finn's net worth.
How do I contact Patrick John Finn?: The corporate mailing address for Mr. Finn and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Patrick John Finn's contact information.
Has Patrick John Finn been buying or selling shares of Verona Pharma?: Patrick John Finn has not been actively trading shares of Verona Pharma over the course of the past ninety days. Learn More on Patrick John Finn's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 19 times. They sold a total of 2,164,281 shares worth more than $13,411,301.36. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/20/2023.

Patrick John Finn Insider Trading History at Verona Pharma

Patrick John Finn Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $15.31

$14.90

$15.45

50 Day Range

MA: $16.37

$15.24

$18.19

2 Week Range

Now: $15.31

$11.83

$23.81

Volume

499,479 shs

Average Volume

496,485 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad